Methods and compositions relating to anti-biotin antibodies
US-2021317232-A1 · Oct 14, 2021 · US
Biotin-specific monoclonal antibody and use thereof
US12360108B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12360108-B2 |
| Application number | US-202117551716-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 15, 2021 |
| Priority date | Dec 27, 2016 |
| Publication date | Jul 15, 2025 |
| Grant date | Jul 15, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generation of an antibody as discloed herein. The monoclonal antibody according to the invention is of specific use in a method for measuring an analyte in a sample, wherein a (strept)avidin/biotin pair is used to bind a biotinylated analyte specific binding agent to a (strept)avidin coated solid phase.
First claim
Opening claim text (preview).
The invention claimed is: 1. An immunogen according to Formula I: wherein: R is Z-L, L-X-Y together are suberyl-beta-alanyl, and Z is a polypeptide of at least 30 amino acids. 2. An immunogen, wherein said immunogen is KLH-suberyl-beta-alanyl-biotin.
Assignees
Inventors
Classifications
- C07K16/44Primary
against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title
containing an intein ("protein splicing")domain · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Ortho-condensed systems · CPC title
involving vitamins {or their receptors} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12360108B2 cover?
- The present invention relates to a monoclonal antibody capable of binding to biotin. In one embodiment the monoclonal antibody according to the invention also does not bind to a biotin moiety on a biotinylated molecule, wherein the biotin moiety is attached to the molecule via the carbon atom of the carboxyl function of the valeric acid moiety of biotin. Also disclosed is a method for generatio…
- Who is the assignee on this patent?
- Roche Diagnostics Operations Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/44. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).